VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ABBVAbbVie Inc.
$216.63$383.2B
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksABBVEarnings History

ABBV logoAbbVie Inc. (ABBV) Earnings History

Earnings Pressure

16 years of earnings data (2010–2025) · 5-year EPS trend is negative

TTM Net Income
$4.23B
● Profitable
TTM EPS (Diluted)
$2.38
Per share, diluted
YoY EPS Growth
-0.8%
Slow
Net Margin
6.9%
After-tax profitability
EPS Growth Rate (CAGR)
1Y-0.8%
3Y-29.0%
5Y-2.7%
10Y-2.7%
Operating Margin32.8%
Gross Margin70.2%
Return on Equity6214.7%
Return on Assets3.1%
Record Annual Net Income$11.84BFY2022
Record Quarterly EPS$2.53Q1 2022
Consecutive Profitable Years16years
Q4 2025
Net Income$1.82B
EPS (Diluted)$1.02
YoY Growth-0.8%Slow
QoQ Growth+876.3%Excellent

Loading earnings history...

AbbVie Inc. (ABBV) Earnings Overview

As of June 21, 2026, AbbVie Inc. (ABBV) reported trailing twelve-month net income of $4.23B, reflecting -0.8% year-over-year growth. The company earned $2.38 per diluted share over the past four quarters, with a net profit margin of 6.9%.

Looking at the long-term picture, ABBV's 5-year EPS compound annual growth rate (CAGR) stands at -2.7%, signaling declining earnings. The company achieved its highest annual net income of $11.84B in fiscal 2022.

AbbVie Inc. maintains positive profitability with a gross margin of 70.2%, operating margin of 32.8%, and net margin of 6.9%. The company continues to generate positive earnings from operations. View revenue history →

Compared to peers including JNJ ($25.12B net income, 15.8% margin), MRK ($18.25B net income, 28.1% margin), PFE ($7.49B net income, 12.4% margin), ABBV has room to improve margins relative to the peer group. Compare ABBV vs JNJ →

ABBV Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ABBV logoABBVCurrent
$4.2B$2.386.9%6214.7%-0.8%—
JNJ logoJNJ
$25.1B$10.3415.8%20.1%-57.8%
MRK logoMRK
$18.3B$7.3428.1%36.9%+8.0%
PFE logoPFE
$7.5B$1.3112.4%8.9%-3.5%
BMY logoBMY
$7.3B$3.5614.6%40.4%+178.2%
LLY logoLLY
$25.3B$28.2131.7%101.2%+96.0%
Best in group
Lowest in group

ABBV Historical Earnings Data (2010–2025)

16 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$4.23B-1.2%$20.09B$2.376.9%32.8%
2024$4.28B-12.0%$9.14B$2.397.6%16.2%
2023$4.86B-58.9%$12.76B$2.729.0%23.5%
2022$11.84B+2.5%$18.12B$6.6320.4%31.2%
2021$11.54B+150.0%$17.92B$6.4520.5%31.9%
2020$4.62B-41.4%$11.36B$2.7210.1%24.8%
2019$7.88B+38.6%$12.98B$5.2823.7%39.0%
2018$5.69B+7.1%$6.38B$3.6817.4%19.5%
2017$5.31B-10.8%$9.54B$3.3018.8%33.8%
2016$5.95B+15.7%$9.34B$3.6323.2%36.4%
2015$5.14B+190.0%$7.54B$3.1322.5%33.0%
2014$1.77B-57.0%$3.41B$1.108.9%17.1%
2013$4.13B-21.7%$5.66B$2.5622.0%30.1%
2012$5.28B+53.7%$5.82B$3.3528.7%31.6%
2011$3.43B-17.8%$3.62B$2.1119.7%20.8%
2010$4.18B-$4.72B$2.5726.7%30.2%

Download Data

Export ABBV earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into ABBV consensus models and risk factors.

View Analysis

Should I Buy ABBV?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

16+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ABBV — Frequently Asked Questions

Quick answers to the most common questions about buying ABBV stock.

What is ABBV earnings per share (EPS)?

ABBV trailing twelve-month (TTM) diluted EPS is $2.38, reflecting -0.8% year-over-year growth. The 5-year EPS CAGR is -2.7%. Complete EPS history from 2010 to 2025 is available in the table on this page.

What is AbbVie Inc.'s net income?

AbbVie Inc. (ABBV) trailing twelve-month net income is $4.2B as of 2025. Earnings declined -0.8% year-over-year. AbbVie Inc. has been profitable for 16 consecutive years.

Is ABBV profitable?

Yes, ABBV is profitable with a TTM net income of $4.2B and a net profit margin of +6.9%. AbbVie Inc. has generated profits for 16 consecutive years.

What is ABBV's earnings growth rate?

ABBV compound annual EPS growth rates (CAGR): 1-Year: -0.8%, 3-Year: -29.0%, 5-Year: -2.7%, 10-Year: -2.7%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2010 to 2025.

What are ABBV's profit margins?

AbbVie Inc. net profit margin is +6.9%, operating margin is +32.8%, and gross margin is +70.2%. Margins are within a typical range for the sector. Return on Equity is +6214.7%.

Is ABBV growing earnings?

ABBV earnings growth is slowing. Current YoY EPS growth of -0.8% trails the 5-year CAGR of -2.7%. TTM net income is $4.2B.

What was ABBV's best earnings year?

AbbVie Inc.'s highest annual net income on record is $11.8B, achieved in fiscal year 2022. Earnings history on this page spans 2010 to 2025 and includes all annual and quarterly figures.

What were ABBV's earnings last quarter?

ABBV's most recent reported quarter was Q4 2025. Net income was $1.8B with diluted EPS of $1.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ABBV Earnings Over Time (2010–2025)

Net income & EPS — annual and quarterly view